BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36143940)

  • 41. Profiling the expression of cytochrome P450 in breast cancer.
    Murray GI; Patimalla S; Stewart KN; Miller ID; Heys SD
    Histopathology; 2010 Aug; 57(2):202-11. PubMed ID: 20716162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathological significance of orphan nuclear receptor Nurr1 expression in gastric cancer.
    Guo J; Zu G; Zhou T; Xing J; Wang Z
    Clin Transl Oncol; 2015 Oct; 17(10):788-94. PubMed ID: 26022133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 45. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
    BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
    Diamandis EP; Borgoño CA; Scorilas A; Yousef GM; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M
    Tumour Biol; 2003; 24(6):299-309. PubMed ID: 15004490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Basigin-2 is the predominant basigin isoform that promotes tumor cell migration and invasion and correlates with poor prognosis in epithelial ovarian cancer.
    Zhao SH; Wang Y; Wen L; Zhai ZB; Ai ZH; Yao NL; Wang L; Liu WC; Chen BL; Li Y; Yang H
    J Transl Med; 2013 Apr; 11():92. PubMed ID: 23566400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of a Novel Potent CYP4Z1 Inhibitor Attenuating the Stemness of Breast Cancer Cells through Lead Optimization.
    Yuan Y; Yao H; Zhou M; Ma X; Zhou Y; Xu J; Niu M; Yin J; Zheng L; Xu S
    J Med Chem; 2022 Dec; 65(23):15749-15769. PubMed ID: 36414390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
    Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
    Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
    Chan KKL; Siu MKY; Jiang YX; Wang JJ; Wang Y; Leung THY; Liu SS; Cheung ANY; Ngan HYS
    BMC Cancer; 2017 Aug; 17(1):606. PubMed ID: 28859612
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
    Chen H; Tian X; Luan Y; Lu H
    Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
    Sayer RA; Lancaster JM; Pittman J; Gray J; Whitaker R; Marks JR; Berchuck A
    Gynecol Oncol; 2005 Feb; 96(2):355-61. PubMed ID: 15661221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
    Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
    [No Abstract]   [Full Text] [Related]  

  • 55. PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer.
    Ma R; Ye X; Cheng H; Ma Y; Cui H; Chang X
    Gynecol Oncol; 2015 Jun; 137(3):546-52. PubMed ID: 25735255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of protease activated receptor-2 in tumor advancement of ovarian cancers.
    Jahan I; Fujimoto J; Alam SM; Sato E; Sakaguchi H; Tamaya T
    Ann Oncol; 2007 Sep; 18(9):1506-12. PubMed ID: 17761706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers.
    Bao LH; Sakaguchi H; Fujimoto J; Tamaya T
    J Biomed Sci; 2007 May; 14(3):373-81. PubMed ID: 17219251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
    Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
    PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells.
    Zheng L; Guo Q; Xiang C; Liu S; Jiang Y; Gao L; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Wang Y; Li X; Xi T
    J Hematol Oncol; 2019 Mar; 12(1):23. PubMed ID: 30832689
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M; Xie X; Ding Y
    Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.